GLPG vs. BPMC, VKTX, IONS, CYTK, SMMT, OGN, MDGL, NUVL, BBIO, and APLS
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Blueprint Medicines (BPMC), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Cytokinetics (CYTK), Summit Therapeutics (SMMT), Organon & Co. (OGN), Madrigal Pharmaceuticals (MDGL), Nuvalent (NUVL), BridgeBio Pharma (BBIO), and Apellis Pharmaceuticals (APLS). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, community ranking, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.
Galapagos has higher revenue and earnings than Blueprint Medicines.
Galapagos presently has a consensus target price of $34.50, indicating a potential upside of 28.92%. Blueprint Medicines has a consensus target price of $108.00, indicating a potential upside of 4.51%. Given Galapagos' higher probable upside, analysts clearly believe Galapagos is more favorable than Blueprint Medicines.
Galapagos has a net margin of -26.25% compared to Blueprint Medicines' net margin of -102.15%. Galapagos' return on equity of -2.60% beat Blueprint Medicines' return on equity.
32.5% of Galapagos shares are held by institutional investors. 2.9% of Galapagos shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Blueprint Medicines had 12 more articles in the media than Galapagos. MarketBeat recorded 13 mentions for Blueprint Medicines and 1 mentions for Galapagos. Blueprint Medicines' average media sentiment score of 0.44 beat Galapagos' score of -0.31 indicating that Blueprint Medicines is being referred to more favorably in the news media.
Blueprint Medicines received 54 more outperform votes than Galapagos when rated by MarketBeat users. Likewise, 67.89% of users gave Blueprint Medicines an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Galapagos has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.
Summary
Blueprint Medicines beats Galapagos on 10 of the 17 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
